Event Date |
06/24/2010 to 06/24/2010 |
Event Location |
Indianapolis IN |
Event Facility |
Sheraton Indianapolis Hotel & Suites
TBD
8787 Keystone Crossing
Indianapolis, IN 46240
|
Agenda |
5:30 5:50 PM Registration & Dinner
5:50 6:00 PM Opening Remarks: Review of Educational Objectives and Case Study
6:00 6:45 PM Plenary session With Q&A
6:45 6:55 PM Break
6:55 7:25 PM Interactive Breakout Sessions: Rounding With the Experts
7:25 7:35 PM Mock Patient Video/Discussion
7:35 8:15 PM Plenary session With Q&A
8:15 8:30 PM Importance of 60-day Outcomes and Closing Remarks
|
Overview |
In addition to the 23.7 million Americans with diabetes, 57 million are estimated to have pre-diabetes. Since approximately 25% of kidney transplant recipients have a history of type 2 diabetes, the prospect of an escalating number of renal transplantations appears to be a foregone conclusion. There is an urgent need for effective strategies to improve long-term allograft and recipient survival.
Factors that negatively impact long-term survival include cardiovascular disease, malignancy, allograft nephropathy, and infection. Effective management requires juggling a fine balance between immunosuppressive efficacy and toxicity, quantified by host rejection, peripheral toxicities and untoward consequences. Despite the increasing number of therapeutic options available, the preferred pharmacotherapeutic approach to achieve this balance is still being investigated. The clinician is now faced with the challenge of evaluating a variety of immunosuppressive approaches that utilize drug minimization, drug elimination, drug avoidance, and drug substitution/conversion.
This program will examine current causes for chronic allograft pathology and approaches to minimize allograft nephropathy through optimal use of immunosuppressive regimens. The ultimate goal of this educational initiative is the clinical application of program content to provide individualized care to solid organ transplant recipients, extending recipient and allograft survival while reducing morbidity.
|
Specialty |
Nephrology
Transplant Nephrology
Transplantation
|
Intended Audience |
This program is intended for transplant surgeons, nephrologists, urologists, nurses, pharmacists, and other health care practitioners involved in the care of renal transplant recipients. |
Registration |
There is no fee to participate in this activity. |
Sponsorship |
This activity is sponsored by SCEPTER and Quintiles Medical Education.
This activity is co-provided by Global Education Group and SCEPTER.
|
Accreditation |
SCEPTER is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Global Education Group is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Centers Commission on Accreditation. |
Credit Designation |
SCEPTER designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Estimated time to complete this activity: 2.5 hours.
This educational activity for 2.5 contact hours is provided by Global Education Group.
|
Pharmacy Credit |
 |
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Global Education Group designates this continuing education activity for 2.5 contact hours ( 2.5 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Program Number 0530-9999-09-027- L01-P) |
Faculty |
Matthew R. Weir, MD - Co-Chairperson
Professor and Director
Division of Nephrology
University of Maryland
School of Medicine
Baltimore, Maryland
Co-presenter: TBD
|
Disclosure |
SCEPTER and Quintiles Medical Education adhere to the ACCME Essential Areas and Policies, including the Standards for Commercial Support, regarding industry support of CME. Disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships, as well as the discussion of unlabeled or unapproved use of any drug, device, or procedure by the faculty, will be disclosed to learners.
|
Grantor Support |
This activity is supported by an educational grant from Novartis.
|
Course Objectives |
- Describe the pathophysiologic basis of chronic allograft nephropathy (CAN ) and how it affects the long-term immunosuppressant management of the transplant recipient
- Explain how maintenance immunosuppressive therapy can be tailored to the transplant recipient based on allograft status, time elapsed post-transplant, and patient characteristics such as ethnicity, history of transplants, and panel reactive antibody (PRA ) status
- Identify immunosuppressive regimens composed of complementary agents that can maximize graft survival and minimize CAN
- Describe patient/health care provider communication tools that can be utilized to promote discussions on medication and health-related topics, effectively involving the transplant recipient in his or her care
|
|
|
|
